The FusionPlex Lung v2 panel is a targeted next-generation sequencing (NGS) research product that expands on our well-adopted FusionPlex Lung panel to further drive discovery. The updated design covers newly published fusion breakpoints and isoforms of interest in key gene targets (including the NTRKs) and aligns with existing guidelines for non-small cell lung cancer research, including NCCN and ESMO (ESCAT). All gene content from the Lung v1 panel is covered in v2, including EGFR vIII and MET exon 14 skipping events along with prominent ALK, BRAF, FGFR, NRG1, NTRK, RET, and ROS1 fusions and select point mutations. The panel is powered by Anchored Multiplex PCR (AMP™) target enrichment chemistry to detect fusions in a single sequencing product, even without prior knowledge of fusion partners or breakpoints.
Comprehensive Fusion Detection
AMP chemistry utilizes open-ended targeted amplification to identify gene fusions whether or not the fusion partner is known.
Detect cancer-associated isoforms and alternative splicing events.
Purpose-built for wide sample type compatibility, including low-input and degraded samples such as FFPE tissue.
Simple, Lyophilized Workflow
Easy-to-handle lyophilized reagents and a simple workflow to minimize errors and reduce turn-around time.
Input Nucleic Acid Required*
Unique Molecular On-Target %
Fresh frozen and FFPE
Illumina® and Ion Torrent™
*Input mass requirements vary depending on type and quality. Unless the tumor cellularity and sample quality are high, 50ng of FFPE-derived nucleic acid should be considered the minimum recommendation. If input is not limiting, 200ng is recommended.